[Pathogenetic approaches to the differentiated drug therapy of hypertension].
Malaia
L T
LT
Vasyl'iev
Iu M
IuM
Babadzhan
V D
VD
Koval'
S N
SN
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D004341:Drug Evaluation; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D018377:Neurotransmitter Agents / Q000097:blood; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D018377:Neurotransmitter Agents; D002216:Captopril; D011433:Propranolol